Pharmacological Strategies for Overcoming Multidrug Resistance to Chemotherapy
Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporte...
Saved in:
| Published in | Pharmaceutical chemistry journal Vol. 56; no. 10; pp. 1307 - 1313 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
2023
Springer |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporters of the 1
st
-4
th
generations. Plant polyphenols, i.e., flavonoids, are commonly referred to as the last (4
th
) generation of MDR inhibitors. Chemosensitizers of different classes should be chosen with allowance for the patient mutation-expression profile and the receptor status of a particular tumor. The appropriate dosage of the chemosensitizer and the administration schedule can enhance the process of counteracting MDR. |
|---|---|
| AbstractList | Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporters of the 1st-4th generations. Plant polyphenols, i.e., flavonoids, are commonly referred to as the last (4th) generation of MDR inhibitors. Chemosensitizers of different classes should be chosen with allowance for the patient mutation-expression profile and the receptor status of a particular tumor. The appropriate dosage of the chemosensitizer and the administration schedule can enhance the process of counteracting MDR. Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporters of the 1 st -4 th generations. Plant polyphenols, i.e., flavonoids, are commonly referred to as the last (4 th ) generation of MDR inhibitors. Chemosensitizers of different classes should be chosen with allowance for the patient mutation-expression profile and the receptor status of a particular tumor. The appropriate dosage of the chemosensitizer and the administration schedule can enhance the process of counteracting MDR. Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporters of the 1.sup.st-4.sup.th generations. Plant polyphenols, i.e., flavonoids, are commonly referred to as the last (4.sup.th) generation of MDR inhibitors. Chemosensitizers of different classes should be chosen with allowance for the patient mutation-expression profile and the receptor status of a particular tumor. The appropriate dosage of the chemosensitizer and the administration schedule can enhance the process of counteracting MDR. Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporters of the 1 -4 generations. Plant polyphenols, i.e., flavonoids, are commonly referred to as the last (4 ) generation of MDR inhibitors. Chemosensitizers of different classes should be chosen with allowance for the patient mutation-expression profile and the receptor status of a particular tumor. The appropriate dosage of the chemosensitizer and the administration schedule can enhance the process of counteracting MDR. |
| Audience | Academic |
| Author | Shimanovsky, N. L. Fedotcheva, T. A. |
| Author_xml | – sequence: 1 givenname: T. A. surname: Fedotcheva fullname: Fedotcheva, T. A. email: tfedotcheva@mail.ru organization: Pirogov Russian National Research Medical University – sequence: 2 givenname: N. L. surname: Shimanovsky fullname: Shimanovsky, N. L. organization: Pirogov Russian National Research Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36683825$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kVtrFTEUhYNU7Gn1D_ggA774MjWZTGaSF6EcvEG14gV8C2myMydlJjlNZgr99-46tVgQCSGQ_a3FXqwjchBTBEKeM3rCKO1fF8aoamvacLy9orV8RDZM9LxWlLMDsqFUsZoJ-vOQHJVySSnKePOEHPKuk1w2YkM-f9mZPBmbxjQEa8bq25zNDEOAUvmUq_NryDZNIQ7Vp2Wcg8vLUH2FEspsooVqTtV2B1Oad5DN_uYpeezNWODZ3XtMfrx7-337oT47f_9xe3pW27blc62865UUngvad9D1kgKD3l2YloNjzAgFzDnMxD1IhJgH23QdtbJhoJzhx-TN6rtfLiZwFiKuPep9DpPJNzqZoB9OYtjpIV1rhbl526HBqzuDnK4WKLOeQrEwjiZCWopu-k5KxkSjEH25ooMZQYfoEzraW1yf9pxL2QoqkDr5B4XHwRQsFucD_j8QNKvA5lRKBn-_PaP6tl-99quxX_27Xy1R9OLv3PeSP4UiwFeg4CgOkPVlWnLELv5n-wt7MrMH |
| CitedBy_id | crossref_primary_10_1007_s11094_024_03043_y crossref_primary_10_1002_cbf_3948 |
| Cites_doi | 10.1016/j.ejmech.2022.114542 10.3390/cancers13174363 10.3390/biom10101429 10.1016/j.ejmech.2017.06.047 10.21873/anticanres.15722 10.3390/molecules27113513 10.1007/s13318-018-0474-x 10.3390/pharmaceutics13101616 10.1371/journal.pone.0254205 10.1016/j.drup.2016.04.003 10.1016/j.drup.2020.100681 10.3390/life12060897 10.1055/a-1803-1744 10.1194/jlr.R900012-JLR200 10.18097/PBMC20146002161 10.3389/fonc.2020.561936 10.3390/molecules27103104 10.1179/joc.2005.17.1.86 10.3390/pharmaceutics13122062 10.1016/0925-4439(92)90131-6 10.3390/biomedicines10030601 10.3390/ijms23094597 10.1016/B978-0-12-816435-8.00004-3 10.3389/fphar.2022.865376 10.1016/j.cbi.2021.109510 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. COPYRIGHT 2023 Springer |
| Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: COPYRIGHT 2023 Springer |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1007/s11094-023-02790-8 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1573-9031 |
| EndPage | 1313 |
| ExternalDocumentID | A733884505 10_1007_s11094_023_02790_8 36683825 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -58 -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 1N0 1SB 2.D 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 4.4 406 408 409 40D 40E 41~ 53G 5QI 5VS 642 67Z 6NX 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDBF ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACTTH ACUDM ACVWB ACWMK ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFGCZ AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BGNMA CAG COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD ESBYG ESX FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG6 HMJXF HQYDN HRMNR HVGLF HZ~ IAO IHE IJ- IKXTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C JBSCW JCJTX JZLTJ KDC KOV KOW LAK LLZTM M4Y MA- MK0 N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P9N PF0 PT4 PT5 QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3B SAP SCLPG SCM SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SZ9 SZN T13 T16 TEORI TSG TSK TSV TUC TUS U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 W4F WJK WK8 XU3 YLTOR Z7U Z7V Z7W Z87 Z8O Z8P Z8Q Z91 ZGI ZMTXR ZOVNA ~8M ~A9 ~EX ~KM AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF H13 NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c443t-9fd7985f35076e6780e1e7dba43ed11a59e1dd2793fe83501fec2660c821e9da3 |
| IEDL.DBID | U2A |
| ISSN | 0091-150X |
| IngestDate | Tue Sep 17 21:30:28 EDT 2024 Fri Oct 25 09:21:15 EDT 2024 Fri Feb 23 00:19:34 EST 2024 Wed Nov 13 00:05:46 EST 2024 Thu Sep 12 16:37:03 EDT 2024 Wed Oct 16 00:39:39 EDT 2024 Sat Dec 16 12:08:01 EST 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | P-glycoprotein tyrosine kinase inhibitors multidrug resistance MRP proteins flavonoids BCRP-protein |
| Language | English |
| License | Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c443t-9fd7985f35076e6780e1e7dba43ed11a59e1dd2793fe83501fec2660c821e9da3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9838346 |
| PMID | 36683825 |
| PQID | 2768811529 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9838346 proquest_miscellaneous_2768811529 gale_infotracmisc_A733884505 gale_infotracacademiconefile_A733884505 crossref_primary_10_1007_s11094_023_02790_8 pubmed_primary_36683825 springer_journals_10_1007_s11094_023_02790_8 |
| PublicationCentury | 2000 |
| PublicationDate | 1-2023 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – year: 2023 text: 1-2023 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Pharmaceutical chemistry journal |
| PublicationTitleAbbrev | Pharm Chem J |
| PublicationTitleAlternate | Pharm Chem J |
| PublicationYear | 2023 |
| Publisher | Springer US Springer |
| Publisher_xml | – name: Springer US – name: Springer |
| References | FedotchevaTAFedotchevaNIShimanovskyNLPharmaceutics2021131016161:CAS:528:DC%2BB3MXivVartrnL10.3390/pharmaceutics13101616 BoichukSDunaevPMustafinIBiomedicines20221036011:CAS:528:DC%2BB38XosVGrtb0%3D10.3390/biomedicines10030601 LimtrakulPKhantamatOPinthaKJ. Chemother.200517186951:CAS:528:DC%2BD2MXjslGitrw%3D10.1179/joc.2005.17.1.86 LaiJ-ITsengY-JChenM-HFront. Oncol.20201010.3389/fonc.2020.561936 DawsonPALanTRaoAJ. Lipid Res.20095012234023571:CAS:528:DC%2BD1MXhsVyrsb7L10.1194/jlr.R900012-JLR200 MatznellerPKussmannMEberlSEur. J. Drug Metab. Pharmacokinet.2018435996061:CAS:528:DC%2BC1cXmvVKisr0%3D10.1007/s13318-018-0474-x YangCMaiZLiuCMolecules2022271135131:CAS:528:DC%2BB38XhsFaqtLfO10.3390/molecules27113513 IbrahimMAAAbdeljawaadKAAAbdelrahmanAHMMolecules2022271031041:CAS:528:DC%2BB38XhsVeksrrF10.3390/molecules27103104 GrigorevaTSagaidakARomanovaAChem. Biol. Interact.20213440951010.1016/j.cbi.2021.109510 EngleKKumarGEur. J. Med. Chem.20222391:CAS:528:DC%2BB38Xhs12gur7J10.1016/j.ejmech.2022.114542 OhYLeeJSLeeJSInt. J. Mol. Sci.202223945971:CAS:528:DC%2BB38Xhtlelsr%2FP10.3390/ijms23094597 LanDWangLHeRAm. J. Transl. Res.2018105129513091:CAS:528:DC%2BC1MXhsVWrt7jK NielsenDSkovsgaardTBiochim. Biophys. Acta1992113931691831:CAS:528:DyaK38XlvVCjtbg%3D10.1016/0925-4439(92)90131-6 JoshiPVishwakarmaRABharateSBEur. J. Med. Chem.20171382732921:CAS:528:DC%2BC2sXhtFegtb3J10.1016/j.ejmech.2017.06.047 W. Wong and L. Fu, “ALK inhibitors as sensitizing agents for cancer chemotherapy,” in: Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy, Z.-S. Chen and D.-H. Yang (eds.), Vol. 4, Cancer Sensitizing Agents for Chemotherapy, B. Bonavida (ed.), (2019), pp. 45 – 52; ISSN 24683183, ISBN 9780128164358; https://doi.org/10.1016/B978-0-12-816435-8.00004-3. RaevskiiOASolodovaSLLaguninAABiomed. Khim.20146021611811:CAS:528:DC%2BC2cXhtVOiu73M10.18097/PBMC20146002161 DongJQinZZhangWDDrug Resist. Updates20204910.1016/j.drup.2020.100681 https://www.selleckchem.com/products/isoquercitrin.html (accessed Aug. 20, 2022). SinghKTarapcsakSGyongyZPharmaceutics2021131220621:CAS:528:DC%2BB38XltlGqtL0%3D10.3390/pharmaceutics13122062 https://www.fda.gov/drugs/development-resources/druginteractions-labeling (accessed Aug. 20, 2022). McCorkleJRGorskiJWLiuJPLoS One20211681:CAS:528:DC%2BB3MXhslKrt7rF10.1371/journal.pone.0254205 OhYLeeJSLeeJSAnticancer Res.2022425243324421:CAS:528:DC%2BB38XhsFKls73F10.21873/anticanres.15722 C. Karthika, R. Sureshkumar, M. Zehravi, et al., Life (Basel, Switz.), 12(6), 897 (2022). Y. Bi, X. Wang, H. Ding, et al., Planta Med., https://doi.org/10.1055/a-1803-1744 (2022). KennedyLSandhuJKHarperMEBiomolecules2020101014291:CAS:528:DC%2BB3cXitF2ntrnO10.3390/biom10101429 GoebelJChmielewskiJHrycynaCACancer Drug Resist.202147848041:CAS:528:DC%2BB3MXit12ltbjO https://pubchem.ncbi.nlm.nih.gov/compound/5280804#section=ClinicalTrials-gov (accessed Aug. 20, 2022). ChenSTangYGaoYFront. Pharmacol.2022131:CAS:528:DC%2BB38XhtlWjurrJ10.3389/fphar.2022.865376 SchindlerBDKaatzGWDrug Resist. Updates2016271131:CAS:528:DC%2BC28XhsFGntr7F10.1016/j.drup.2016.04.003 NeophytouCMTrougakosIPErinNCancers (Basel)2021131743631:CAS:528:DC%2BB3MXisFCqs7vN10.3390/cancers13174363 https://pubchem.ncbi.nlm.nih.gov/compound/5280343#section=ClinicalTrials-gov (accessed Aug. 20, 2022). Drugbank: https://go.drugbank.com/drugs/ (accessed Aug. 20, 2022). PA Dawson (2790_CR10) 2009; 50 D Nielsen (2790_CR8) 1992; 1139 L Kennedy (2790_CR3) 2020; 10 MAA Ibrahim (2790_CR9) 2022; 27 2790_CR14 JR McCorkle (2790_CR28) 2021; 16 TA Fedotcheva (2790_CR7) 2021; 13 2790_CR15 Y Oh (2790_CR30) 2022; 42 2790_CR31 D Lan (2790_CR4) 2018; 10 J Goebel (2790_CR16) 2021; 4 K Engle (2790_CR5) 2022; 239 C Yang (2790_CR25) 2022; 27 P Joshi (2790_CR12) 2017; 138 2790_CR17 J-I Lai (2790_CR32) 2020; 10 S Boichuk (2790_CR13) 2022; 10 S Chen (2790_CR23) 2022; 13 K Singh (2790_CR26) 2021; 13 Y Oh (2790_CR29) 2022; 23 BD Schindler (2790_CR6) 2016; 27 J Dong (2790_CR27) 2020; 49 P Limtrakul (2790_CR19) 2005; 17 2790_CR24 CM Neophytou (2790_CR1) 2021; 13 OA Raevskii (2790_CR11) 2014; 60 2790_CR20 2790_CR21 2790_CR22 T Grigoreva (2790_CR2) 2021; 344 P Matzneller (2790_CR18) 2018; 43 |
| References_xml | – volume: 239 year: 2022 ident: 2790_CR5 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2022.114542 contributor: fullname: K Engle – volume: 13 start-page: 4363 issue: 17 year: 2021 ident: 2790_CR1 publication-title: Cancers (Basel) doi: 10.3390/cancers13174363 contributor: fullname: CM Neophytou – volume: 10 start-page: 1429 issue: 10 year: 2020 ident: 2790_CR3 publication-title: Biomolecules doi: 10.3390/biom10101429 contributor: fullname: L Kennedy – volume: 138 start-page: 273 year: 2017 ident: 2790_CR12 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2017.06.047 contributor: fullname: P Joshi – volume: 42 start-page: 2433 issue: 5 year: 2022 ident: 2790_CR30 publication-title: Anticancer Res. doi: 10.21873/anticanres.15722 contributor: fullname: Y Oh – volume: 27 start-page: 3513 issue: 11 year: 2022 ident: 2790_CR25 publication-title: Molecules doi: 10.3390/molecules27113513 contributor: fullname: C Yang – volume: 43 start-page: 599 year: 2018 ident: 2790_CR18 publication-title: Eur. J. Drug Metab. Pharmacokinet. doi: 10.1007/s13318-018-0474-x contributor: fullname: P Matzneller – ident: 2790_CR15 – volume: 4 start-page: 784 year: 2021 ident: 2790_CR16 publication-title: Cancer Drug Resist. contributor: fullname: J Goebel – volume: 13 start-page: 1616 issue: 10 year: 2021 ident: 2790_CR7 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics13101616 contributor: fullname: TA Fedotcheva – volume: 16 issue: 8 year: 2021 ident: 2790_CR28 publication-title: PLoS One doi: 10.1371/journal.pone.0254205 contributor: fullname: JR McCorkle – ident: 2790_CR14 – volume: 27 start-page: 1 year: 2016 ident: 2790_CR6 publication-title: Drug Resist. Updates doi: 10.1016/j.drup.2016.04.003 contributor: fullname: BD Schindler – volume: 49 year: 2020 ident: 2790_CR27 publication-title: Drug Resist. Updates doi: 10.1016/j.drup.2020.100681 contributor: fullname: J Dong – volume: 10 start-page: 1295 issue: 5 year: 2018 ident: 2790_CR4 publication-title: Am. J. Transl. Res. contributor: fullname: D Lan – ident: 2790_CR17 doi: 10.3390/life12060897 – ident: 2790_CR22 – ident: 2790_CR20 doi: 10.1055/a-1803-1744 – volume: 50 start-page: 2340 issue: 12 year: 2009 ident: 2790_CR10 publication-title: J. Lipid Res. doi: 10.1194/jlr.R900012-JLR200 contributor: fullname: PA Dawson – volume: 60 start-page: 161 issue: 2 year: 2014 ident: 2790_CR11 publication-title: Biomed. Khim. doi: 10.18097/PBMC20146002161 contributor: fullname: OA Raevskii – ident: 2790_CR24 – volume: 10 year: 2020 ident: 2790_CR32 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.561936 contributor: fullname: J-I Lai – volume: 27 start-page: 3104 issue: 10 year: 2022 ident: 2790_CR9 publication-title: Molecules doi: 10.3390/molecules27103104 contributor: fullname: MAA Ibrahim – volume: 17 start-page: 86 issue: 1 year: 2005 ident: 2790_CR19 publication-title: J. Chemother. doi: 10.1179/joc.2005.17.1.86 contributor: fullname: P Limtrakul – volume: 13 start-page: 2062 issue: 12 year: 2021 ident: 2790_CR26 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics13122062 contributor: fullname: K Singh – volume: 1139 start-page: 169 issue: 3 year: 1992 ident: 2790_CR8 publication-title: Biochim. Biophys. Acta doi: 10.1016/0925-4439(92)90131-6 contributor: fullname: D Nielsen – volume: 10 start-page: 601 issue: 3 year: 2022 ident: 2790_CR13 publication-title: Biomedicines doi: 10.3390/biomedicines10030601 contributor: fullname: S Boichuk – volume: 23 start-page: 4597 issue: 9 year: 2022 ident: 2790_CR29 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms23094597 contributor: fullname: Y Oh – ident: 2790_CR31 doi: 10.1016/B978-0-12-816435-8.00004-3 – volume: 13 year: 2022 ident: 2790_CR23 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.865376 contributor: fullname: S Chen – ident: 2790_CR21 – volume: 344 start-page: 09510 year: 2021 ident: 2790_CR2 publication-title: Chem. Biol. Interact. doi: 10.1016/j.cbi.2021.109510 contributor: fullname: T Grigoreva |
| SSID | ssj0010032 |
| Score | 2.3202305 |
| Snippet | Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP... |
| SourceID | pubmedcentral proquest gale crossref pubmed springer |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1307 |
| SubjectTerms | Cancer Chemotherapy Drug resistance in microorganisms Isoflavones Medicine Molecular-Biological Problems of Drug Design and Mechanism of Drug Action Organic Chemistry Pharmacology/Toxicology Pharmacy Polyphenols Proteins |
| Title | Pharmacological Strategies for Overcoming Multidrug Resistance to Chemotherapy |
| URI | https://link.springer.com/article/10.1007/s11094-023-02790-8 https://www.ncbi.nlm.nih.gov/pubmed/36683825 https://search.proquest.com/docview/2768811529 https://pubmed.ncbi.nlm.nih.gov/PMC9838346 |
| Volume | 56 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Pb9MwFH4amwS7IFZ-LDAmI6FxoJGS2E3sYzetm0ArE1qlcrLS2AYuKVraQ_973nOSZqkQ0k5RZbex_T37fe7z-wzwMZWqcCZSYWpsFlLOMs65KA-dtArpfSGkv5LlZppez8SX-Wje5XH7w-5tRNIv1F2uWxyRim3iw46U__wEDkYkh4ZGPEvG29ABmmktEa7iENnOvMmU-fdv9LzR7pr8wCntHpjciZp6ZzR5Ac8bFsnGNexHsGfLATy7aC9vG8DTmyZmPoCz21qdejNkd12yVTVkZ-y2063evITpg48EHWuVa23FkNqyb2j1OFbYIObTds39-if7bitioGg6bLVk1IImpWvzCmaTy7uL67C5biEshOCrUDmTKTlyHCliatGJRTa2mVnkglsTx_lI2dgYHDfurKR4pLMFuveokElslcn5a9gvl6U9BpZkNloo0q6PnIiFUwuXElTCIWESkgfwuR12_adW1dCdfjKBpBEk7UHSMoBPhIymKYcdL_ImcwDfReJVepzhPlsK5HIBnPRq4qAXveIPLbaaiuh8WWmX60onuOuSSI4TFcCbGuttw3iaSo4b6QCynhVsK5BCd7-k_P3LK3Ur_CIXaQDD1l50s0RU_-nv28dVfweHiTdp-l_oBPZX92v7HpnSanEKB-PJ-fmUnlc_vl6e-pnyF7KDDGg |
| link.rule.ids | 230,315,783,787,888,27936,27937,41093,41535,42162,42604,52123,52246 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1db9MwFL2CTmK88FEYBAYYCY0HmimJXcd-rKaNwtYyoVYqT1YS2zBNStGSPpRfz3U-2qVCSHus7La-zrF9nOtzDPCBC5lZHUifaxP7TrOMYy5IfCuMRHqfMVFdyTKZ8vGcfV0MF40orGhPu7cpyWqm3ordwsDZ2EZV3tEJoO_DHotCHvVgb_T5x_npJnuASK1dwmXoI-FZNGKZf_9KZ0HanZZvrUu7ZyZ3EqfVenT2GOZtJPUxlOvjVZkeZ392TB7vGuoTeNQQVDKqEfUU7pm8D_sn7b1wfXgwadLxfTi6rI2v1wMy2-q4igE5IpdbS-z1M5je-uhQQVpTXFMQZM3kGw4obBq2kVSKYH2z-km-m8KRW0QlKZfEtaBRi62fw_zsdHYy9pubHPyMMVr60upYiqGlyD65wfUxMKGJdZowanQYJkNpQq0xVGqNcKlOazJkDkEmotBIndAD6OXL3LwEEsUmSKWzxQ8sC5mVqeXOFI9Z5GJMUA8-tY9T_a4NO9TWmtn1q8J-VVW_KuHBR_fElRvNGHiWNKIE_C_ni6VGMW7hBUOa6MFhpyZ2etYpft9iRrkid3QtN8tVoSLc0Ank3ZH04EWNoU3DKOeC4h7dg7iDrk0FZ_7dLcmvflUm4BK_SBn3YNBCSDWzT_GfeF_drfo72B_PJhfq4sv0_DU8jCpEutdPh9Arb1bmDRKyMn3bjL-_1tspqQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD6CThq8cCm3wAAjofFAs-XiJvZjNVYGY6VCm1SerCS2N4SUTkv6UH495-TSNhVCQjxGdhsf53P8OcffZ4C3kZCZ1Z50I21ilzTLOOa8xLXCSKT3GRfVkSxnk-jkgn-eDWcbKv5qt3ubkqw1DeTSlJeH19oeroVvvkeWtkGVgyQx9G3Y4eSM1IOd0cfvp8erTAKitnYMl76L5GfWCGf-_C-dyWn7Fb0xR23vn9xKolZz0_g-JG1U9ZaUnweLMj3Ifm0ZPv5P2A_gXkNc2ahG2kO4ZfI-3Dlqz4vrw-5Zk6bvw_60NsReDtj5Wt9VDNg-m66tspePYLJxSWhhrVmuKRiyafYVBxo2E9vLKqWwvllcsm-mINKLaGXlnFELGhXZ8jFcjI_Pj07c5oQHN-M8LF1pdSzF0IbISiOD86ZnfBPrNOGh0b6fDKXxtcZQQ2sEpUCtyZBReJkIfCN1Ej6BXj7PzTNgQWy8VJJdvme5z61MbURmedwiR-MidOB9-2jVdW3kodaWzdSvCvtVVf2qhAPv6OkrGuUYeJY0YgW8F_llqVGMS3vBkT46sNepiZ2edYrftPhRVERb2nIzXxQqwIWeQD4eSAee1nhaNSyMIhHi2t2BuIO0VQUyBe-W5D-uKnNwiT8MeeTAoIWTat5KxV_iff5v1V_D7vTDWH35NDl9AXeDCpD0VWoPeuXNwrxEnlamr5qh-Bux-TKN |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacological+Strategies+for+Overcoming+Multidrug+Resistance+to+Chemotherapy&rft.jtitle=Pharmaceutical+chemistry+journal&rft.au=Fedotcheva%2C+T.+A&rft.au=Shimanovsky%2C+N.+L&rft.date=2023-01-01&rft.pub=Springer&rft.issn=0091-150X&rft.volume=56&rft.issue=10&rft.spage=1307&rft_id=info:doi/10.1007%2Fs11094-023-02790-8&rft.externalDocID=A733884505 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-150X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-150X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-150X&client=summon |